Stelic Institute & Co. provides a series of innovative drugs in our pipeline for anti-fibrotic medicines. The drug pipeline contains 2 kinds of candidates: selective anti-glycogene RNAi therapeutics for intractable fibrosis, and small molecule inhibitors targeting distinct glycogenes for life-style or age-related fibrosis. We focus initially on the RNAi-based drug STNM01 for Crohn’s disease stricture, with which we have accumulated specialized know-how in both the clinic and the lab. Our lead product STNM01 must provide great impact on the patients’ quality of life since current interventional therapy under hospitalization will be largely replaced by less-invasive treatment. We will sequentially create small molecule glycan inhibitors for the treatment of other chronic fibrotic diseases like NASH, COPD, Dementia, PD, CKD, DR, and so on.
Current pipeline of Stelic’s drug candidates
In addition, we have also conducted a translational research program to isolate fibrosis-related quantitative biomarkers, which can translate from pre-clinical studies to clinical practice and contribute to the development of anti-fibrotic therapeutics. Based on the development platform, which will be achieved by the concept-proving medicine STNM01, modularization of the development process for anti-fibrosis therapeutics will also be established. The modularization will contribute to cost reduction and shorten the timeline of sequential development of anti-fibrotic therapeutics.
- For STNM01, we are seeking a co-development partner who has a strong interest in this space.
- For small molecule glycan inhibitors, we are seeking a strategic business partner with expertise in developing and optimizing the candidates to launching the drug into the market.
We bring several intellectual assets to the table, including our modularizing program and glycogene-based validation in the development of anti-fibrosis therapeutics.
